Abstract Details

Title Next Generation Tablet-based Digital Clock Drawing Task for Characterizing Change to Cognitive Status

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-002

Background The Clock Drawing Task (CDT) is a well validated, noninvasive, and rapid cognitive screening tool in use for over 50 years. We previously reported the development and validation of a digital pen-and-paper version of the CDT, DCTclock™, that is FDA approved and commercially available. DCTclock automatically extracts the cognitive and motor processes of the drawing process. However, DCTclock relies on expensive digital pens and disposable paper forms. We recently developed a tablet-based version of the dCDT that can be administered with a stylus to further decrease the cost and improve the accessibility of these cognitive tools.

Objective To determine whether a novel tablet-based digital Clock Drawing Task (dCDT) is equivalent to the pen-based dCDT by evaluating the relationship to a gold standard cognitive screening tool, the Mini-Mental Status Exam (MMSE).

Design/Methods We completed a randomized crossover clinical trial to evaluate equivalence between the alternative forms of the dCDT. Subjects (N=195, 115 males, mean age 65.84 ± 8.45, range 55-91) were randomly assigned to receive either the tablet- or pen-version at their first visit, as well as the MMSE. After a washout period, subjects received the other dCDT version. We tested agreement between the alternate versions and MMSE using weighted Cohen’s kappa statistics, a measurement of classification reliability between repeated tests.

Results Mean weighted Cohen’s kappa coefficients between the MMSE and the alternate versions of the dCDT were highly similar: κDCTclock-pen=0.16, κDCTclock-tablet=0.2. Additionally, mean Pearson correlation coefficients between raw MMSE and both versions were similar: ??DCTclock-pen=0.31, ??DCTclock-tablet=0.36.

Conclusions Our results indicate as strong a relationship between the tablet-based dCDT and the MMSE as with the pen-based dCDT, supporting our a-priori hypothesis of equivalence between the tablet-based and pen-based dCDT. The tablet-based dCDT represents a scalable, efficient, and validated dementia screening assessment that has higher sensitivity than available devices and methods.

Authors/Disclosures
Timothy Helbig (Linus Health) PRESENTER	Mr. Helbig has received personal compensation for serving as an employee of Linus Health. Mr. Helbig has received personal compensation for serving as an employee of edX.
William A. Souillard-Mandar (Digital Cognition Technologies)	No disclosure on file
Connor P. Higgins, Other (Linus Health)	Mr. Higgins has received personal compensation for serving as an employee of Infosys Ltd.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Alvaro Pascual-Leone, MD, PhD, FAAN (Marcus Institute for Aging Research & Wolk Center for Memory Health)	Dr. Pascual-Leone has received personal compensation for serving as an employee of Linus Health. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Magstim. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroelectrics. Dr. Pascual-Leone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TetraNeuron. Dr. Pascual-Leone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedRhythms. Dr. Pascual-Leone has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Linus Health. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. Dr. Pascual-Leone has stock in TI Solutions. The institution of Dr. Pascual-Leone has received research support from NIH. The institution of Dr. Pascual-Leone has received research support from NSF. The institution of Dr. Pascual-Leone has received research support from Brightfocus Foundation . Dr. Pascual-Leone has received intellectual property interests from a discovery or technology relating to health care. Dr. Pascual-Leone has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file